Compare Torrent Pharma with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ALKEM LABORATORIES - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ALKEM LABORATORIES TORRENT PHARMA/
ALKEM LABORATORIES
 
P/E (TTM) x 38.4 24.5 156.9% View Chart
P/BV x 9.7 5.9 164.6% View Chart
Dividend Yield % 0.6 0.8 76.3%  

Financials

 TORRENT PHARMA   ALKEM LABORATORIES
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-19
ALKEM LABORATORIES
Mar-20
TORRENT PHARMA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,9642,720 72.2%   
Low Rs1,2451,660 75.0%   
Sales per share (Unadj.) Rs453.4697.9 65.0%  
Earnings per share (Unadj.) Rs25.896.1 26.8%  
Cash flow per share (Unadj.) Rs62.3117.3 53.1%  
Dividends per share (Unadj.) Rs17.0025.00 68.0%  
Dividend yield (eoy) %1.11.1 92.8%  
Book value per share (Unadj.) Rs279.2515.2 54.2%  
Shares outstanding (eoy) m169.22119.57 141.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.53.1 112.8%   
Avg P/E ratio x62.222.8 273.1%  
P/CF ratio (eoy) x25.818.7 137.9%  
Price / Book Value ratio x5.74.3 135.2%  
Dividend payout %65.926.0 253.5%   
Avg Mkt Cap Rs m271,513261,879 103.7%   
No. of employees `00013.614.3 94.9%   
Total wages/salary Rs m14,03815,055 93.2%   
Avg. sales/employee Rs Th5,642.65,822.6 96.9%   
Avg. wages/employee Rs Th1,032.41,050.5 98.3%   
Avg. net profit/employee Rs Th320.9802.0 40.0%   
INCOME DATA
Net Sales Rs m76,72883,444 92.0%  
Other income Rs m5711,042 54.7%   
Total revenues Rs m77,29984,486 91.5%   
Gross profit Rs m19,83114,734 134.6%  
Depreciation Rs m6,1772,528 244.4%   
Interest Rs m5,038651 774.3%   
Profit before tax Rs m9,18712,598 72.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5700-   
Tax Rs m1,2541,105 113.5%   
Profit after tax Rs m4,36311,493 38.0%  
Gross profit margin %25.817.7 146.4%  
Effective tax rate %13.68.8 155.6%   
Net profit margin %5.713.8 41.3%  
BALANCE SHEET DATA
Current assets Rs m50,37554,960 91.7%   
Current liabilities Rs m51,65332,433 159.3%   
Net working cap to sales %-1.727.0 -6.2%  
Current ratio x1.01.7 57.6%  
Inventory Days Days9280 115.7%  
Debtors Days Days6872 94.7%  
Net fixed assets Rs m83,64832,710 255.7%   
Share capital Rs m846239 353.9%   
"Free" reserves Rs m46,39761,368 75.6%   
Net worth Rs m47,24461,607 76.7%   
Long term debt Rs m39,1291,592 2,457.2%   
Total assets Rs m141,20999,433 142.0%  
Interest coverage x2.820.4 13.9%   
Debt to equity ratio x0.80 3,204.3%  
Sales to assets ratio x0.50.8 64.7%   
Return on assets %6.712.2 54.5%  
Return on equity %9.218.7 49.5%  
Return on capital %12.321.0 58.8%  
Exports to sales %019.1 0.0%   
Imports to sales %03.0 0.0%   
Exports (fob) Rs mNA15,917 0.0%   
Imports (cif) Rs mNA2,483 0.0%   
Fx inflow Rs m22,10316,061 137.6%   
Fx outflow Rs m5,5222,483 222.4%   
Net fx Rs m16,58113,578 122.1%   
CASH FLOW
From Operations Rs m17,9815,851 307.3%  
From Investments Rs m-2,413-7,414 32.5%  
From Financial Activity Rs m-13,145792 -1,660.7%  
Net Cashflow Rs m2,380-731 -325.6%  

Share Holding

Indian Promoters % 71.5 66.9 106.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.0 33.1 21.2%  
FIIs % 12.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 0.0 -  
Shareholders   26,511 68,381 38.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   DR. DATSONS LABS  BIOCON   J.B.CHEMICALS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 27.0% (Quarterly Result Update)

Oct 27, 2020 | Updated on Oct 27, 2020

For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 48.6% (Quarterly Result Update)

Jul 31, 2020 | Updated on Jul 31, 2020

For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


May 11, 2021 03:36 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS